Who is sponsoring NCT01632306?

NCT01632306 is sponsored by Eli Lilly and Company.

What condition does NCT01632306 study?

NCT01632306 studies Pancreatic Cancer.

What drugs are being tested in NCT01632306?

Interventions: LY2090314, FOLFOX, Gemcitabine, Nab-paclitaxel.

What is the status of NCT01632306?

NCT01632306 is currently TERMINATED.

Last reviewed 2019-01-11 · How we verify

Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy

NCT01632306 Phase 1/Phase 2 TERMINATED Results posted

Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 1/Phase 2
Status	TERMINATED
Enrolment	13
Start date	2013-03
Completion	2015-06

Conditions

Pancreatic Cancer

Interventions

LY2090314
FOLFOX
Gemcitabine
Nab-paclitaxel

Primary outcomes

Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation — Baseline, 4 Hours Post-Treatment on Day 0
Change in the phosphorylation level of glycogen synthase, a glycogen synthase kinase-3 beta (GSK-3beta) inhibitor, from baseline to 4 hours post-treatment on day 0 using tumor tissue and blood specimens.

Countries

United States